1-13 of 13
Mihaela Popa-McKiver
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Clinical Trials & Observations
Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesús Berdeja, Sergio Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa McKiver, Paula Rodríguez-Otero
Journal: Blood
Blood (2024) 144 (23): 2389–2401.
https://doi.org/10.1182/blood.2024024582
Published: 2024
Includes: Supplemental data
Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial

Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio A. Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa-McKiver, Mark Cook, Paula Rodriguez Otero
Journal: Blood
Blood (2023) 142 (Supplement 1): 96.
https://doi.org/10.1182/blood-2023-179152
Published: 2023
Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Triple-Class-Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Who Received at Least 3 Lines of Prior Antimyeloma Regimens in the KarMMa-3 Phase 3 Randomized Controlled Trial

Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio A. Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa-McKiver, Mark Cook, Paula Rodríguez Otero
Journal: Blood
Blood (2023) 142 (Supplement 1): 1003.
https://doi.org/10.1182/blood-2023-173849
Published: 2023
Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Paula Rodríguez Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Luciano Costa, Ravi Vij, Nizar J Bahlis, Philippe Moreau, Scott R. Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur S. Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesus G. Berdeja, Anna Truppel-Hartmann, Rashmi Bhatnagar, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa-McKiver, Sergio A. Giralt
Journal: Blood
Blood (2023) 142 (Supplement 1): 1028.
https://doi.org/10.1182/blood-2023-178933
Published: 2023
Journal Articles

Patient (pt) Experiences of Receiving Idecabtagene Vicleucel (Ide-Cel, bb2121) Versus Standard (Std) Regimens for the Treatment (Tx) of Relapsed/Refractory Multiple Myeloma (RRMM) in the Randomized, Controlled KarMMa-3 Clinical Trial: Analysis of Longitudinal Qualitative Interviews

Paula Rodríguez Otero, Krina K. Patel, Noopur S. Raje, Olga Moshkovich, Heather Gerould, Jennifer Devlen, Devender Dhanda, Laurie Eliason, Mark Cook, Mihaela Popa-McKiver, Salomon Manier
Journal: Blood
Blood (2023) 142 (Supplement 1): 2385.
https://doi.org/10.1182/blood-2023-173840
Published: 2023
Journal Articles

Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study

Katja Weisel, Agne Paner, MD, Monika Engelhardt, MD, Fiona Taylor, Kim Cocks, Mihaela Popa-McKiver, PhD, Clara Chen, PhD BS, MS, Michele Cavo
Journal: Blood
Blood (2019) 134 (Supplement_1): 3480.
https://doi.org/10.1182/blood-2019-122232
Published: 2019
Journal Articles

Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone +/- Elotuzumab

Ann Forslund, PhD, Hao Tang, Chunzhe Duan, Mihaela Popa-McKiver, PhD, James R. Berenson, MD, Michael Robbins, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1853.
https://doi.org/10.1182/blood-2019-128760
Published: 2019
Journal Articles

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Mitsuo Hori, MD PhD, Naoki Takezako, MD PhD, Kazutaka Sunami, MD PhD, Shigeki Ito, MD PhD, Junya Kuroda, MD PhD, Mihaela Popa-McKiver, PhD, Ying-Ming Jou, Suresh G. Shelat, PhD, Masafumi Miyoshi, Kenshi Suzuki, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3260.
https://doi.org/10.1182/blood-2018-99-116225
Published: 2018
Journal Articles

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study

Sundar Jagannath, MD, Jesus G. Berdeja, MD, Robert M Rifkin, MD, Craig E. Cole, MD, Michael Alan Thompson, MD PhD, Ravi Vij, MBBS, Mihaela Popa-McKiver, PhD, Rao Saleem, Oumar Sy, PhD, William Bensinger, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1991.
https://doi.org/10.1182/blood-2018-99-112077
Published: 2018
Journal Articles

Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study

Katja Weisel, MD, Agne Paner, MD, Monika Engelhardt, MD, Fiona Taylor, Kim Cocks, Ashlee Espensen, Mihaela Popa-McKiver, PhD, Clara Chen, PhD BS, MS, Michele Cavo, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2288.
https://doi.org/10.1182/blood-2018-99-112080
Published: 2018
Journal Articles

A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039)

Stephen Ansell, MD PhD, Martin E Gutierrez, MD, Margaret A. Shipp, MD, Douglas Gladstone, MD, Alison Moskowitz, Ivan Borello, Mihaela Popa-Mckiver, Benedetto Farsaci, Lili Zhu, MS, Alexander M. Lesokhin, MD, Philippe Armand, MD PhD
Journal: Blood
Blood (2016) 128 (22): 183.
https://doi.org/10.1182/blood.V128.22.183.183
Published: 2016
Journal Articles

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma

Philippe Armand, MD PhD, Pier Luigi Zinzani, MD PhD, Graham P. Collins, MD PhD, Jonathon B. Cohen, MD, Ahmad S. Halwani, MD, Carmelo Carlo-Stella, MD, Michael M. Millenson, MD, Mariano Provencio, MD PhD, Eva Domingo Domenech, MD, Lisa Giulino Roth, MD, Luca Castagna, MD, Kazunobu Kato, MD, Mihaela Popa McKiver, Anne Sumbul, Lili Zhu, MS, Armando Santoro, MD
Journal: Blood
Blood (2016) 128 (22): 3502.
https://doi.org/10.1182/blood.V128.22.3502.3502
Published: 2016
Journal Articles

Age Is the Strongest Independent Prognostic Factor in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: Moffitt Cancer Center Experience

Costanza Paoletti, Lodovico Balducci, MD, Ivette Boler, RN, Mihaela Popa-McKiver, MD, PhD, Martine Externann, MD, PhD, Jyotishankar Raychaudury, MD, Claudio Anasetti, MD, Hugo F. Fernandez, MD, Daniel Sullivan, MD, MS, William S. Dalton, MD, PhD, Teresa Field, Ernesto Ayala, MD, Mohamed A Kharfan-Dabaja, MD, Lia Perez, MD, Janelle Perkins, William E. Janssen, PhD, John Harris, Michael Schell, Rachna Kapoor, MD, MPH, Melissa Alsina, J. Leonel Ochoa-Bayona
Journal: Blood
Blood (2008) 112 (11): 4435.
https://doi.org/10.1182/blood.V112.11.4435.4435
Published: 2008